XBIO — Xenetic Biosciences Share News
0.000.00%
Last trade - 00:00- $4.03m
- -$2.44m
- $2.98m
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Xenetic Biosciences Q2 royalty revenue rises on Takeda sublicense
Xenetic Biosciences' Q1 royalty revenue rises, net loss narrows
Xenetic Biosciences Q3 revenue up 67.2% on royalty gains
Xenetic Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Xenetic Biosciences Inc expected to post a loss of 64 cents a share - Earnings Preview
Xenetic Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Xenetic Biosciences Inc expected to post a loss of 72 cents a share - Earnings Preview
Xenetic Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Xenetic Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Xenetic Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary
Xenetic Biosciences Inc expected to post a loss of 83 cents a share - Earnings Preview
Brief: Xenetic Biosciences Appoints CFO James Parslow As Co's Interim CEO
Xenetic Biosciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Xenetic Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Xenetic Biosciences Inc expected to post a loss of 87 cents a share - Earnings Preview
Xenetic Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Xenetic Biosciences Inc expected to post a loss of $1.13 a share - Earnings Preview
Brief: Xenetic Biosciences Announces Reverse Stock Split Of Common Stock